Search Within

Early Drug Development Service

Formats
  1. Meeting Abstract (236)
  2. Journal Article (210)
  3. Review (7)
  4. Editorial (5)
  5. Research Letter (3)
  6. Miscellaneous (2)
  7. Book Section (1)
Groups
  1. Department of Medicine (464)
  2. Solid Tumor Oncology Division (464)
  3. GSK Faculty (245)
  4. Department of Pathology and Laboratory Medicine (201)
  5. Human Oncology and Pathogenesis Program (194)
  6. Gynecologic Medicine Service (188)

More Groups

People
  1. David Hyman (354)
  2. Alison Schram (125)
  3. Alexander Drilon (112)
  4. Michael Berger (111)
  5. David Solit (110)
  6. Marc Ladanyi (91)

More People

Years
  1. 2025 (9)
  2. 2024 (29)
  3. 2023 (18)
  4. 2022 (27)
  5. 2021 (27)
  6. 2020 (49)

More Years

Publications
  1. Journal of Clinical Oncology (113)
  2. Annals of Oncology (38)
  3. Cancer Research (37)
  4. Clinical Cancer Research (33)
  5. Cancer Discovery (23)
  6. Blood (21)

More Publications

Publishers
  1. American Society of Clinical Oncology (128)
  2. American Association for Cancer Research (101)
  3. Oxford University Press (45)
  4. Elsevier Inc. (34)
  5. Nature Publishing Group (29)
  6. American Society of Hematology (23)

More Publishers

Results (464)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)
    Meeting Abstract

    Carneiro, B. A.; Rosen, E.; Fontana, E.; Lee, E. K.; Mettu, N. B.; Lheureux, S.; Plummer, R.; Silverman, I. M.; Schonhoft, J. D.; Yang, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
    Meeting Abstract

    Vieito, M.; McKean, M.; Spira, A. I.; Rosen, E.; Rodon, J.; Garcia, V. M.; Gambardella, V.; Saavedra, O.; Cousin, S.; Cassier, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER plus metastatic breast cancer
    Meeting Abstract

    Rosen, E.; Caswell-Jin, J.; Berz, D.; Mai, N.; Fulgar, G.; Densel, M.; Chiang, G.; Sperry, S.; Warner, D.; Meric-Bernstam, F.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Genotypically-selected pan cancer trial of camonsertib with palliative radiation in the treatment of metastatic tumors harboring an ataxia-telangiectasia mutated (ATM) mutation
    Meeting Abstract

    Lee, N. Y.; Michelle, R.; Huang, M.; Guo, R.; Ferreira, V.; Merril, M.; Sgroe, E.; Unger, T.; Koehler, M.; Setton, J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation
    Meeting Abstract

    Schram, A.; Shapiro, G.; Thompson, J.; Vandross, A.; Kummar, S.; El-Khoueiry, A.; LeDuke, K.; Fellous, M.; Alland, L.; Dumbrava, E.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)
    Meeting Abstract

    Schram, A.; Eskander, R.; Sill, M.; Hagemann, A.; Waggoner, S.; Press, J.; Ghamande, S.; Zivanovic, O.; Bottsford-Miller, J.; Aghajanian, C.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
    Meeting Abstract

    Højgaard, M.; Yap, T. A.; Lee, E. K.; Weiss, M. C.; Lheureux, S.; Simpkins, F.; LoRusso, P.; Carneiro, B. A.; Moy, R. H.; Aguado-Fraile, E.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): The ReFocus study
    Meeting Abstract

    Hollebecque, A.; Dotan, E.; Liao, C. Y. A.; Roda, D.; Fontana, E.; Babiker, H.; Kim, R. D.; Oh, D. Y.; Ghiringhelli, F.; Moreno, I.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Genotype-directed synthetic cytotoxicity of ATR inhibition with radiotherapy
    Journal Article

    Ng, V.; Sinha, S.; Novaj, A.; Ma, J.; McDermott, N.; Pei, X.; Longhini, A. L. F.; Grimsley, H.; Gardner, R.; Rosen, E.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save